This small-cap stock surged 75% since IPO price but ICICI Securities sets target below CMP; what should shareholders do?
60-Word AI Digest
Sudeep Pharma shares have climbed nearly 75% above their IPO price, but ICICI Securities says expectations for its emerging battery materials business are already reflected in the valuation. The brokerage retained its Hold rating while raising its target price to ₹1,000.
Key Takeaways
- Sudeep Pharma shares have climbed nearly 75% above their IPO price, but ICICI Securities says expectations for its emerging battery materials business are already reflected in the valuation.
- The brokerage retained its Hold rating while raising its target price to ₹1,000.
- Full details and original dispatch available below.
Sudeep Pharma shares have climbed nearly 75% above their IPO price, but ICICI Securities says expectations for its emerging battery materials business are already reflected in the valuation. The brokerage retained its Hold rating while raising its target price to ₹1,000.
Original Publisher Attribution
This summary was curated from Livemint.